Immunopathological Analysis in a French National Cohort of Membranous Nephropathy

Condition(s) studied

Investigational drug(s) / intervention(s)

Blood sample: Serum samples will be sent for centralised analyses in Nice. On these samples, different analysis will be performed : * anti-PLA2R1 and anti-THSD7A antibodies * anti-PLA2R1 and anti-THSD7A epitopes * HLA typing

Study summary

National cohort of all cases of membranous nephropathy (MN) during a 1 year period in France, based on a pathological and/or serological diagnostic, collecting the data on:

* incidence of MN
* prevalence of anti-PLA2R1 and anti-THSD7A
* clinical outcome one year after diagnosis or after relapse (complete remission, partial remission or persistent nephrotic syndrome)
* environmental risk factors for the onset of MN
* HLA markers
* patient care status in France

Eligibility

Primary outcome measure(s)

• To determine the incidence of Membranous Nephropathy (MN) and its evolution — one year after inclusion
  as either complete remission (UPCR \< 0.3 g/g, serum albumin \> 35 g/L, eGFR \> 60 ml/min/1.73 m²) or partial remission (UPCR \< 3.5 g/g and reduction of at least 50% from baseline, \< 20% increase of serum creatinin from baseline) or persistent nephrotic syndrome (UPCR \> 3.5 g/g, serum albumin \< 30 g/L)

Trial sites (1)

More Centre Hospitalier Universitaire de Nice trials in France

Other trials for the same condition